



Press release from Emotra AB (publ)  
Göteborg, February 15, 2021

## Data on depression relapse published in BMC Psychiatry

**An article on the first study on the connection between hyporeactivity and increased risk of depression relapse has been published in the scientific journal BMC Psychiatry. The article shows that the likelihood of depression relapse is almost five times higher in hyporeactive patients.**

The scientific article "*Clinical effectiveness of the electrodermal orienting reactivity test for evaluating relapse and recurrence risk in patients hospitalized for depression*" has now been published in BMC Psychiatry.

The study was carried out on in-patients tested with EDOR® test with a follow-up period of approximately 10 months. The results show that the likelihood of depression relapse within 10 months after hospital discharge was three times higher among hyporeactive individuals compared to reactive patients.

When so-called confounding factors, such as gender and number and duration of previous depression episodes, were included in the analysis, the difference between the groups became even more evident. The likelihood of hyporeactive patients suffering a depression relapse was then almost five times higher compared to reactive patients. The study only examined hyporeactivity associated with depression relapse. None of the other variables analysed in the study were found to be associated with relapse.

Link to the article: <https://bmcp psychiatry.biomedcentral.com/articles/10.1186/s12888-021-03088-3>

These results will now need to be confirmed in a larger, multi-centre study, which we plan on launching in 2021, on condition that the current Corona pandemic will allow it. These scientific data and market research projects completed have been important factors for Emotra's decision to focus the use of EDOR on depression relapse. This new focus offers good opportunities to broaden the application area of the method.

**For further information, please contact:** Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

EMOTRA AB, AstraZeneca BioVentureHub, Pepparedsleden 1  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)